Artefenomel (OZ439) + Ferroquine (SSR97193)
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Plasmodium Falciparum Infection
Conditions
Plasmodium Falciparum Infection
Trial Timeline
Sep 11, 2018 → Nov 6, 2019
NCT ID
NCT03660839About Artefenomel (OZ439) + Ferroquine (SSR97193)
Artefenomel (OZ439) + Ferroquine (SSR97193) is a phase 2 stage product being developed by Sanofi for Plasmodium Falciparum Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03660839. Target conditions include Plasmodium Falciparum Infection.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03660839 | Phase 2 | Completed |
Competing Products
13 competing products in Plasmodium Falciparum Infection
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KLU156 + Coartem | Novartis | Phase 3 | 77 |
| artemether:lumefantrine (2.5 mg:30 mg) | Novartis | Phase 2/3 | 65 |
| INE963 | Novartis | Phase 2 | 52 |
| KAE609 + Piperaquine Phosphate | Novartis | Phase 1 | 33 |
| KAE609 + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + Coartem + Lumefantrine Solid Dispersion Formulation | Novartis | Phase 2 | 52 |
| Artemether-lumefantrine | Novartis | Phase 3 | 77 |
| INE963 + KAE609 (Cipargamin) + SoC (Coartem) + KLU156 | Novartis | Phase 2 | 52 |
| KAF156 + LUM-SDF + Coartem | Novartis | Phase 2 | 52 |
| Azithromycin/Chloroquine + Sulfadoxine-Pyrimethamine/Chloroquine | Pfizer | Phase 2/3 | 64 |
| Ferroquine (SSR97193) + Placebo + artesunate | Sanofi | Phase 2 | 51 |
| Ferroquine SSR97193 + Artefenomel | Sanofi | Phase 2 | 51 |
| Meplazumab for Injection + Sterile normal saline (0.9%) | Pacific Biosciences | Phase 1 | 25 |